Evidence map›Paper›PMID 40556904›Full record

ArticleFrontiers in public health2025

The current status, trends, and challenges of Alzheimer's disease and other dementias in Asia (1990-2036).

Ziyang He, Haoqin Zhang, Guishan Hu, Yinan Qiao, Can Yin, Jianqiao Li, Hong Lin, Anguo Wu, Dalian Qin, Betty Yuen-Kwan Law and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
  3. Article
  4. Review
  5. Review
  6. Article
  7. Regulation of autophagy-mediated pathways by diet, physical activity, and sleep in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ziyang He *Sichuan Key Medical Laboratory of New Drug Discovery and Druggability Evaluation, School of Pharmacy, Southwest Medical University, Luzhou, China.
Haoqin Zhang *Sichuan Key Medical Laboratory of New Drug Discovery and Druggability Evaluation, School of Pharmacy, Southwest Medical University, Luzhou, China.
Guishan HuSichuan Key Medical Laboratory of New Drug Discovery and Druggability Evaluation, School of Pharmacy, Southwest Medical University, Luzhou, China.
Yinan QiaoClinic Medical College, Southwest Medical University, Luzhou, China.
Can YinSichuan Key Medical Laboratory of New Drug Discovery and Druggability Evaluation, School of Pharmacy, Southwest Medical University, Luzhou, China.
Jianqiao LiSichuan Key Medical Laboratory of New Drug Discovery and Druggability Evaluation, School of Pharmacy, Southwest Medical University, Luzhou, China.
Hong LinDepartment of Anatomy, School of Basic Medical Sciences, Southwest Medical University, Luzhou, China.
Anguo WuSichuan Key Medical Laboratory of New Drug Discovery and Druggability Evaluation, School of Pharmacy, Southwest Medical University, Luzhou, China.
Dalian QinSichuan Key Medical Laboratory of New Drug Discovery and Druggability Evaluation, School of Pharmacy, Southwest Medical University, Luzhou, China.
Betty Yuen-Kwan LawState Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Taipa, Macao SAR, China.
Guangqiang HuDepartment of Anatomy, School of Basic Medical Sciences, Southwest Medical University, Luzhou, China.
Lu YuSichuan Key Medical Laboratory of New Drug Discovery and Druggability Evaluation, School of Pharmacy, Southwest Medical University, Luzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: With global aging, Alzheimer's disease (AD) and other dementias have emerged as significant health threats to the older adults, garnering considerable attention due to their impact on public health. Despite the substantial burden of dementia in Asia, targeted research remains limited. This study aims to assess the current burden, future trends, risk factors, and inequalities in Asia. Method: The GBD 2021 study was utilized to evaluate the numbers and age-standardized rates (ASRs) of prevalence, mortality, and disability-adjusted life-years (DALYs) of AD and other dementias from 1990 to 2021. Joinpoint regression analysis was performed to assess the trends during this period, while the Autoregressive Integrated Moving Average (ARIMA) model was employed to predict future trends. Additionally, the relationship between disease burden and sociodemographic index (SDI) was also analyzed. Results: In 2021, Asia experienced a 250.44% increase in prevalent cases, a 297.34% rise in mortality, and a 249.54% surge in DALYs for AD and other dementias compared to 1990. Meanwhile, the age-standardized prevalence rate, age-standardized mortality rate, and age-standardized DALY rate also exhibited varying degrees of rise from 1990 to 2021. Demographically, the disease burden was higher in women and those aged 65 and above. Regionally, the burden was highest in East Asia and relatively low in South and Central Asia. Nationally, China, India, Japan, and Indonesia reported the most cases. Over the next 15 years, the age-standardized prevalence rate in Asia is expected to peak in 2028 before declining, while the age-standardized mortality rate is anticipated to keep rising. An overall "V" shaped association was found between sociodemographic index (SDI) and the age-standardized DALY rate in Asia. Only smoking, high fasting plasma glucose (FPG), and high BMI were identified as causal risk factors within the GBD framework. Conclusion: The burden of AD and other dementias in Asia has significantly increased over the past three decades and is expected to persistently impact Asian populations, particularly in developing countries experiencing rapid demographic shifts. Women and the older adult should be a focus of attention. It is imperative to implement targeted prevention and intervention strategies, enhance chronic disease management, and control risk factors.

Indexed as

Alzheimer DiseaseDementiaAgedAged, 80 and overAsiaCost of IllnessDisability-Adjusted Life YearsFemaleHumansMaleMiddle AgedPrevalenceRisk FactorsAlzheimer’s disease and other dementiadisability-adjusted life yearsglobal burden of diseasemortalityprevalencerisk factors

Identifiers

PMID40556904
PMCPMC12185285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.